Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients.

Robledo G, Márquez A, Dávila-Fajardo CL, Ortego-Centeno N, Rubio JL, Garrido Ede R, Sánchez-Román J, García-Hernández FJ, Ríos-Fernández R, González-Escribano MF, García MT, Palma MJ, Ayala Mdel M, Martín J.

DNA Cell Biol. 2012 Dec;31(12):1671-7. doi: 10.1089/dna.2012.1799. Epub 2012 Oct 17.

PMID:
23075294
2.

Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases.

Robledo G, Dávila-Fajardo CL, Márquez A, Ortego-Centeno N, Callejas Rubio JL, de Ramón Garrido E, Sánchez-Román J, García-Hernández FJ, Ríos-Fernández R, González-Escribano MF, Camps García MT, Castillo Palma MJ, Ayala Mdel M, Martín J.

DNA Cell Biol. 2012 Sep;31(9):1486-91. doi: 10.1089/dna.2012.1684. Epub 2012 Jun 26.

PMID:
22734797
3.

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H.

Blood. 2002 Feb 1;99(3):754-8.

4.

IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients.

Márquez A, Dávila-Fajardo CL, Robledo G, Rubio JL, de Ramón Garrido E, García-Hernández FJ, González-León R, Ríos-Fernández R, Barrera JC, González-Escribano MF, García MT, Palma MJ, del Mar Ayala M, Ortego-Centeno N, Martín J.

Mol Biol Rep. 2013 Aug;40(8):4851-6. doi: 10.1007/s11033-013-2583-6. Epub 2013 May 5.

PMID:
23645042
5.

Impact of allele copy number of polymorphisms in FCGR3A and FCGR3B genes on susceptibility to ulcerative colitis.

Asano K, Matsumoto T, Umeno J, Hirano A, Esaki M, Hosono N, Matsui T, Kiyohara Y, Nakamura Y, Kubo M, Kitazono T.

Inflamm Bowel Dis. 2013 Sep;19(10):2061-8. doi: 10.1097/MIB.0b013e318298118e.

PMID:
23917248
6.

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.

Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G.

Blood. 2012 Sep 27;120(13):2650-7. Epub 2012 Aug 10.

7.

Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.

Zimmermann H, Weiland T, Nourse JP, Gandhi MK, Reinke P, Neuhaus R, Karbasiyan M, Gärtner B, Anagnostopoulos I, Riess H, Trappe RU, Oertel S.

J Immunol Res. 2014;2014:264723. doi: 10.1155/2014/264723. Epub 2014 Feb 10.

8.

The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis.

Liu D, Tian Y, Sun D, Sun H, Jin Y, Dong M.

Ann Hematol. 2016 Sep;95(9):1483-90. doi: 10.1007/s00277-016-2723-x. Epub 2016 Jul 19.

PMID:
27431582
9.

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G.

Cancer Res. 2004 Jul 1;64(13):4664-9.

10.

Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.

Burkhardt B, Yavuz D, Zimmermann M, Schieferstein J, Kabickova E, Attarbaschi A, Lisfeld J, Reiter A, Makarova O, Worch J, Bonn BR, Damm-Welk C.

Ann Hematol. 2016 Sep;95(9):1503-12. doi: 10.1007/s00277-016-2731-x. Epub 2016 Jul 4.

PMID:
27376362
11.

Accurate interrogation of FCGR3A rs396991 in European and Asian populations using a widely available TaqMan genotyping method.

Murphy KE, Niederer HA, King KS, Harris EC, Glass SM, Cox CJ.

Pharmacogenet Genomics. 2015 Nov;25(11):569-72. doi: 10.1097/FPC.0000000000000175.

12.

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK.

Blood. 2006 Oct 15;108(8):2720-5. Epub 2006 Apr 11.

13.

Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.

Ternant D, Cartron G, Hénin E, Tod M, Girard P, Paintaud G.

Br J Clin Pharmacol. 2012 Apr;73(4):597-605. doi: 10.1111/j.1365-2125.2011.04125.x.

14.

Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.

Cooper N, Stasi R, Cunningham-Rundles S, Cesarman E, McFarland JG, Bussel JB.

Br J Haematol. 2012 Aug;158(4):539-47. doi: 10.1111/j.1365-2141.2012.09184.x. Epub 2012 Jul 6.

PMID:
22775462
15.

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.

Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S.

Ann Rheum Dis. 2014 Apr;73(4):716-21. doi: 10.1136/annrheumdis-2012-202435. Epub 2013 Mar 16.

PMID:
23505228
16.

Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma.

Keane C, Nourse JP, Crooks P, Nguyen-Van D, Mutsando H, Mollee P, Lea RA, Gandhi MK.

Intern Med J. 2012 Oct;42(10):1113-9. doi: 10.1111/j.1445-5994.2011.02587.x.

PMID:
21883784
17.

FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.

Nishio M, Endo T, Fujimoto K, Yamamoto S, Obara M, Yamaguchi K, Takeda Y, Goto H, Kasahara I, Sato N, Koike T.

Eur J Haematol. 2009 Feb;82(2):143-7. doi: 10.1111/j.1600-0609.2008.01174.x. Epub 2008 Nov 6.

PMID:
19018870
18.

Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis.

Morgan AW, Robinson JI, Barrett JH, Martin J, Walker A, Babbage SJ, Ollier WE, Gonzalez-Gay MA, Isaacs JD.

Arthritis Res Ther. 2006;8(4):R109.

19.

Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease.

Rohatgi S, Gohil S, Kuniholm MH, Schultz H, Dufaud C, Armour KL, Badri S, Mailliard RB, Pirofski LA.

MBio. 2013 Aug 27;4(5):e00573-13. doi: 10.1128/mBio.00573-13.

20.

Effect of FCGR2A and FCGR3A variants on CLL outcome.

Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Wenger MK, Weisser M.

Blood. 2010 Nov 18;116(20):4212-22. doi: 10.1182/blood-2010-03-272765. Epub 2010 Aug 12.

Supplemental Content

Support Center